17. 多系統萎縮症 Multiple system atrophy Clinical trials / Disease details


臨床試験数 : 119 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111

  
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03446807
(ClinicalTrials.gov)
December 202120/2/2018Safety and Efficacy of Droxidopa for Fatigue in Patients With ParkinsonismSafety and Efficacy of Droxidopa for Fatigue in Patients With ParkinsonismParkinson Disease;Multiple System Atrophy;Progressive Supranuclear PalsyDrug: Droxidopa;Drug: Placebo Oral TabletLoma Linda UniversityH. Lundbeck A/SNot yet recruiting50 YearsN/AAll32Phase 2United States
2NCT02897063
(ClinicalTrials.gov)
September 20167/9/2016Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic FailureThe Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy;Parkinson Disease;Orthostatic HypotensionDrug: Droxidopa;Drug: Midodrine;Drug: PlaceboVanderbilt University Medical CenterNULLRecruiting40 Years80 YearsAll34Phase 1United States
3NCT02071459
(ClinicalTrials.gov)
January 21, 201421/2/2014Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSAEvaluate the Long-term (3 Months) Efficacy of L-threo DOPS (DroxiDopa) on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With Multiple System Atrophy (MSA). Comparative Study Versus PlaceboMultiple System AtrophyDrug: L-Threo DOPS;Drug: placeboUniversity Hospital, ToulouseNULLCompleted30 Years80 YearsAll107Phase 2/Phase 3France
4NCT00738062
(ClinicalTrials.gov)
January 200819/8/2008Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic HypotensionNeurogenic Orthostatic Hypotension;Non-Diabetic Autonomic Neuropathy;Multiple System Atrophy;Dopamine Beta Hydroxylase DeficiencyDrug: Droxidopa;Drug: PlaceboChelsea TherapeuticsNULLCompleted18 YearsN/AAll103Phase 3United States;Australia;Canada;New Zealand
5NCT00547911
(ClinicalTrials.gov)
October 200719/10/2007Augmenting Effects of L-DOPS With Carbidopa and EntacaponeL-Dihydroxyphenylserine (L-DOPS) for Norepinephrine Deficiency: Interactions With Carbidopa and EntacaponeParkinson Disease;Multiple System Atrophy;Autonomic Nervous System DiseasesDrug: Droxidopa;Drug: Carbidopa;Drug: EntacaponeNational Institute of Neurological Disorders and Stroke (NINDS)NULLTerminated18 YearsN/AAll14Phase 1/Phase 2United States
6NCT00004478
(ClinicalTrials.gov)
March 199918/10/1999Droxidopa in Treating Patients With Neurogenic HypotensionStudy of Droxidopa in Patients With Neurologic HypotensionShy-Drager Syndrome;Orthostatic HypotensionDrug: droxidopaMount Sinai School of MedicineNULLCompleted20 YearsN/ABothN/AUnited States